Clinical Documentation: Connecting the Dots | Join Webinar & Earn 1 AAPC® CEURegister Now >>

ICD-10-PCS Code Lookup

PCS Tables

XW0

X New Technology
W Anatomical Regions
0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Body Part Approach Device / Substance / Technology Qualifier
Character 4 Character 5 Character 6 Character 7
Body System (Character 4)
1 Subcutaneous Tissue
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
W Caplacizumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
2 Ceftazidime-Avibactam Anti-infective
3 Idarucizumab, Dabigatran Reversal Agent
4 Isavuconazole Anti-infective
5 Blinatumomab Antineoplastic Immunotherapy
Qualifier (Character 7)
1 New Technology Group 1
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
7 Coagulation Factor Xa, Inactivated
9 Defibrotide Sodium Anticoagulant
Qualifier (Character 7)
2 New Technology Group 2
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
A Bezlotoxumab Monoclonal Antibody
B Cytarabine and Daunorubicin Liposome Antineoplastic
C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy
F Other New Technology Therapeutic Substance
Qualifier (Character 7)
3 New Technology Group 3
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G Plazomicin Anti-infective
H Synthetic Human Angiotensin II
Qualifier (Character 7)
4 New Technology Group 4
Body System (Character 4)
3 Peripheral Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
K Fosfomycin Anti-infective
N Meropenem-vaborbactam Anti-infective
Q Tagraxofusp-erzs Antineoplastic
S Iobenguane I-131 Antineoplastic
U Imipenem-cilastatin-relebactam Anti-infective
W Caplacizumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
2 Ceftazidime-Avibactam Anti-infective
3 Idarucizumab, Dabigatran Reversal Agent
4 Isavuconazole Anti-infective
5 Blinatumomab Antineoplastic Immunotherapy
Qualifier (Character 7)
1 New Technology Group 1
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
7 Coagulation Factor Xa, Inactivated
9 Defibrotide Sodium Anticoagulant
Qualifier (Character 7)
2 New Technology Group 2
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
A Bezlotoxumab Monoclonal Antibody
B Cytarabine and Daunorubicin Liposome Antineoplastic
C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy
F Other New Technology Therapeutic Substance
Qualifier (Character 7)
3 New Technology Group 3
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
G Plazomicin Anti-infective
H Synthetic Human Angiotensin II
Qualifier (Character 7)
4 New Technology Group 4
Body System (Character 4)
4 Central Vein
Approach (Character 5)
3 Percutaneous
Substance (Character 6)
K Fosfomycin Anti-infective
N Meropenem-vaborbactam Anti-infective
Q Tagraxofusp-erzs Antineoplastic
S Iobenguane I-131 Antineoplastic
U Imipenem-cilastatin-relebactam Anti-infective
W Caplacizumab
Qualifier (Character 7)
5 New Technology Group 5
Body System (Character 4)
D Mouth and Pharynx
Approach (Character 5)
X External
Substance (Character 6)
8 Uridine Triacetate
Qualifier (Character 7)
2 New Technology Group 2
Body System (Character 4)
D Mouth and Pharynx
Approach (Character 5)
X External
Substance (Character 6)
J Apalutamide Antineoplastic
L Erdafitinib Antineoplastic
R Venetoclax Antineoplastic
T Ruxolitinib
V Gilteritinib Antineoplastic
Qualifier (Character 7)
5 New Technology Group 5